82 related articles for article (PubMed ID: 25119312)
21. Bone mineral density changes after 2 years of ARV treatment, compared to naive HIV-1-infected patients not on HAART.
Rey D; Treger M; Sibilia J; Priester M; Bernard-Henry C; Cheneau C; Javier RM
Infect Dis (Lond); 2015 Feb; 47(2):88-95. PubMed ID: 25426996
[TBL] [Abstract][Full Text] [Related]
22. Bone mineral density, growth, and thyroid function in long-term survivors of pediatric Hodgkin's lymphoma treated with chemotherapy only.
van Beek RD; van den Heuvel-Eibrink MM; Hakvoort-Cammel FG; van den Bos C; van der Pal HJ; Krenning EP; de Rijke YB; Pieters R; de Muinck Keizer-Schrama SM
J Clin Endocrinol Metab; 2009 Jun; 94(6):1904-9. PubMed ID: 19293271
[TBL] [Abstract][Full Text] [Related]
23. Bone mineral density changes following discontinuation of ronacaleret treatment: off-treatment extension of a randomized, dose-finding phase II trial.
Fitzpatrick LA; Wooddell M; Dabrowski CE; Cicconetti G; Gordon DN
Bone; 2014 Oct; 67():104-8. PubMed ID: 24794093
[TBL] [Abstract][Full Text] [Related]
24. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer.
Smith MR; McGovern FJ; Zietman AL; Fallon MA; Hayden DL; Schoenfeld DA; Kantoff PW; Finkelstein JS
N Engl J Med; 2001 Sep; 345(13):948-55. PubMed ID: 11575286
[TBL] [Abstract][Full Text] [Related]
25. Oral hormone therapy with 17beta-estradiol and 17beta-estradiol in combination with norethindrone acetate in the prevention of bone loss in early postmenopausal women: dose-dependent effects.
Greenwald MW; Gluck OS; Lang E; Rakov V
Menopause; 2005; 12(6):741-8. PubMed ID: 16278618
[TBL] [Abstract][Full Text] [Related]
26. Switch from tenofovir to raltegravir increases low bone mineral density and decreases markers of bone turnover over 48 weeks.
Bloch M; Tong WW; Hoy J; Baker D; Lee FJ; Richardson R; Carr A;
HIV Med; 2014 Jul; 15(6):373-80. PubMed ID: 24460797
[TBL] [Abstract][Full Text] [Related]
27. Effect of chemotherapy on skeletal health in male survivors from testicular cancer and lymphoma.
Brown JE; Ellis SP; Silcocks P; Blumsohn A; Gutcher SA; Radstone C; Hancock BW; Hatton MQ; Coleman RE
Clin Cancer Res; 2006 Nov; 12(21):6480-6. PubMed ID: 17085662
[TBL] [Abstract][Full Text] [Related]
28. Short-term changes in bone turnover markers and bone mineral density response to parathyroid hormone in postmenopausal women with osteoporosis.
Bauer DC; Garnero P; Bilezikian JP; Greenspan SL; Ensrud KE; Rosen CJ; Palermo L; Black DM
J Clin Endocrinol Metab; 2006 Apr; 91(4):1370-5. PubMed ID: 16449339
[TBL] [Abstract][Full Text] [Related]
29. Bone mineral density and bone turnover markers in patients receiving a single course of isotretinoin for nodulocystic acne.
Tekin NS; Ozdolap S; Sarikaya S; Keskin SI
Int J Dermatol; 2008 Jun; 47(6):622-5. PubMed ID: 18477161
[TBL] [Abstract][Full Text] [Related]
30. Prognostic analysis of Japanese men with metastatic germ cell tumors showing favorable response to bleomycin, etoposide and cisplatin as first-line chemotherapy.
Kumano M; Miyake H; Hara I; Muramaki M; Takenaka A; Fujisawa M
Hinyokika Kiyo; 2007 Dec; 53(12):851-6. PubMed ID: 18203521
[TBL] [Abstract][Full Text] [Related]
31. Alterations in bone mineral density and bone turnover markers in newly diagnosed adults with lymphoma receiving chemotherapy: a 1-year prospective pilot study.
Paccou J; Merlusca L; Henry-Desailly I; Parcelier A; Gruson B; Royer B; Charbonnier A; Ursu D; Desailloud R; Garidi R; Kamel S; Sevestre H; Marolleau JP; Fardellone P; Damaj G
Ann Oncol; 2014 Feb; 25(2):481-6. PubMed ID: 24401926
[TBL] [Abstract][Full Text] [Related]
32. The effect of transvaginal estradiol on bone in aged women: a randomised controlled trial.
Salminen HS; Sääf ME; Johansson SE; Ringertz H; Strender LE
Maturitas; 2007 Aug; 57(4):370-81. PubMed ID: 17493777
[TBL] [Abstract][Full Text] [Related]
33. Associations between bone mineral density and subclinical atherosclerosis: a cross-sectional study of a Chinese population.
Liang DK; Bai XJ; Wu B; Han LL; Wang XN; Yang J; Chen XM
J Clin Endocrinol Metab; 2014 Feb; 99(2):469-77. PubMed ID: 24248180
[TBL] [Abstract][Full Text] [Related]
34. A 24-month study evaluating the efficacy and safety of denosumab for the treatment of men with low bone mineral density: results from the ADAMO trial.
Langdahl BL; Teglbjærg CS; Ho PR; Chapurlat R; Czerwinski E; Kendler DL; Reginster JY; Kivitz A; Lewiecki EM; Miller PD; Bolognese MA; McClung MR; Bone HG; Ljunggren Ö; Abrahamsen B; Gruntmanis U; Yang YC; Wagman RB; Mirza F; Siddhanti S; Orwoll E
J Clin Endocrinol Metab; 2015 Apr; 100(4):1335-42. PubMed ID: 25607608
[TBL] [Abstract][Full Text] [Related]
35. [Accretion of bone mass in patients treated for childhood acute lymphoblastic leukemia].
Muszyńska-Rosłan K; Konstantynowicz J; Krawczuk-Rybak M
Pol Merkur Lekarski; 2007 Oct; 23(136):271-5. PubMed ID: 18293849
[TBL] [Abstract][Full Text] [Related]
36. Improvement in bone mineral density and body composition in survivors of childhood acute lymphoblastic leukemia: a 1-year prospective study.
Marinovic D; Dorgeret S; Lescoeur B; Alberti C; Noel M; Czernichow P; Sebag G; Vilmer E; Léger J
Pediatrics; 2005 Jul; 116(1):e102-8. PubMed ID: 15995009
[TBL] [Abstract][Full Text] [Related]
37. A new active vitamin D, ED-71, increases bone mass in osteoporotic patients under vitamin D supplementation: a randomized, double-blind, placebo-controlled clinical trial.
Matsumoto T; Miki T; Hagino H; Sugimoto T; Okamoto S; Hirota T; Tanigawara Y; Hayashi Y; Fukunaga M; Shiraki M; Nakamura T
J Clin Endocrinol Metab; 2005 Sep; 90(9):5031-6. PubMed ID: 15972580
[TBL] [Abstract][Full Text] [Related]
38. Corticosteroid effects on proximal femur bone loss.
Sambrook P; Birmingham J; Kempler S; Kelly P; Eberl S; Pocock N; Yeates M; Eisman J
J Bone Miner Res; 1990 Dec; 5(12):1211-6. PubMed ID: 2075834
[TBL] [Abstract][Full Text] [Related]
39. Risk of low bone mineral density in testicular germ cell cancer survivors: association with hypogonadism and treatment modality.
Isaksson S; Bogefors K; Åkesson K; Egund L; Bobjer J; Leijonhufvud I; Giwercman A
Andrology; 2017 Sep; 5(5):898-904. PubMed ID: 28591464
[TBL] [Abstract][Full Text] [Related]
40. Bone density and structure in healthy postmenopausal women treated with exemestane for the primary prevention of breast cancer: a nested substudy of the MAP.3 randomised controlled trial.
Cheung AM; Tile L; Cardew S; Pruthi S; Robbins J; Tomlinson G; Kapral MK; Khosla S; Majumdar S; Erlandson M; Scher J; Hu H; Demaras A; Lickley L; Bordeleau L; Elser C; Ingle J; Richardson H; Goss PE
Lancet Oncol; 2012 Mar; 13(3):275-84. PubMed ID: 22318095
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
